Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J's Reminyl Adds Mortality Precaution For Mild Cognitive Impairment

This article was originally published in The Pink Sheet Daily

Executive Summary

The Precautions section of labeling cites two Reminyl studies in patients with mild cognitive impairment in which the treatment-group mortality rate exceeded that of the placebo arm. J&J issues a "Dear Health Care Professional" letter alerting prescribers to the revised labeling.

You may also be interested in...



Reminyl Gets New Name – Razadyne – Ahead Of ER Launch

The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.

Reminyl Gets New Name – Razadyne – Ahead Of ER Launch

The name change for the Alzheimer's product follows reports of medication errors with Sanofi-Aventis' diabetes product Amaryl. J&J agreed to change the name prior to launching the extended-release version of galantamine, which will be available in pharmacies in May.

Reminyl Safety Signal Reported In Two Cognitive Impairment Studies

FDA and foreign health authorities are investigating mortality rates from two galantamine studies in the treatment of mild cognitive impairment, Johnson & Johnson says. The studies did not demonstrate Reminyl efficacy in the indication.

Topics

UsernamePublicRestriction

Register

LL111799

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel